Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.

Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA.

Schizophr Res. 2008 Oct;105(1-3):175-87. doi: 10.1016/j.schres.2008.07.006. Epub 2008 Sep 4.

2.

The CATIE schizophrenia trial: results, impact, controversy.

Manschreck TC, Boshes RA.

Harv Rev Psychiatry. 2007 Sep-Oct;15(5):245-58. Review.

PMID:
17924259
3.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Review.

PMID:
23055416
4.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
5.

Olanzapine versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654. doi: 10.1002/14651858.CD006654.pub2. Review.

6.

Risperidone versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626. doi: 10.1002/14651858.CD006626.pub2. Review.

7.

The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.

Thomas P.

Eur Neuropsychopharmacol. 2007 Mar;17 Suppl 2:S115-22. Review.

PMID:
17336766
8.

Quetiapine versus other atypical antipsychotics for schizophrenia.

Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S.

Cochrane Database Syst Rev. 2013 Nov 18;(11):CD006625. doi: 10.1002/14651858.CD006625.pub3. Review.

PMID:
24249315
9.
10.

Ziprasidone versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006627. doi: 10.1002/14651858.CD006627.pub2. Review.

11.

What do large scale studies of medication in schizophrenia add to our management strategies?

Agius M, Davis A, Gilhooley M, Chapman S, Zaman R.

Psychiatr Danub. 2010 Jun;22(2):323-8. Review.

12.

Dyslipidemia and atypical antipsychotic drugs.

Casey DE.

J Clin Psychiatry. 2004;65 Suppl 18:27-35. Review.

13.

Clozapine versus other atypical antipsychotics for schizophrenia.

Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD006633. doi: 10.1002/14651858.CD006633.pub2. Review.

14.

Quetiapine versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006625. doi: 10.1002/14651858.CD006625.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;11:CD006625.

15.

Antipsychotics and metabolics in the post-CATIE era.

Meyer JM.

Curr Top Behav Neurosci. 2010;4:23-42. Review.

PMID:
21312396
16.

Risperidone (depot) for schizophrenia.

Sampson S, Hosalli P, Furtado VA, Davis JM.

Cochrane Database Syst Rev. 2016 Apr 14;4:CD004161. doi: 10.1002/14651858.CD004161.pub2. Review.

PMID:
27078222

Supplemental Content

Support Center